Reviewing Solid Biosciences (SLDB) & Acorda Therapeutics (ACOR)

Solid Biosciences (NASDAQ:SLDB) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility & Risk

Solid Biosciences has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Solid Biosciences and Acorda Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences 1 5 2 0 2.13
Acorda Therapeutics 2 5 2 0 2.00

Solid Biosciences presently has a consensus price target of $32.67, indicating a potential upside of 221.84%. Acorda Therapeutics has a consensus price target of $21.25, indicating a potential upside of 45.55%. Given Solid Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Solid Biosciences is more favorable than Acorda Therapeutics.


This table compares Solid Biosciences and Acorda Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solid Biosciences N/A -63.10% -45.38%
Acorda Therapeutics 7.14% 12.98% 6.09%

Institutional and Insider Ownership

68.3% of Solid Biosciences shares are held by institutional investors. 7.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Solid Biosciences and Acorda Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences N/A N/A -$52.11 million ($2.88) -3.52
Acorda Therapeutics $471.43 million 1.48 $33.68 million $1.82 8.02

Acorda Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.


Acorda Therapeutics beats Solid Biosciences on 8 of the 12 factors compared between the two stocks.

About Solid Biosciences

Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About Acorda Therapeutics

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with's FREE daily email newsletter.